Loading organizations...
§ Private Profile · Burlington, MA, USA
Wearable and At-Home protein monitoring with silicon photonic chips
SiPhox Health has raised $33.0M across 3 funding rounds.
Key people at SiPhox Health.
SiPhox Health was founded in 2020 by Diedrik Vermeulen (Founder) and Michael Dubrovsky (Co-Founder).
SiPhox Health has raised $33.0M in total across 3 funding rounds.
We are developing a new paradigm for consumer health tech wearables by replacing a 100lb optical instrument with an area of silicon smaller than a postage stamp.
Key people at SiPhox Health.
SiPhox Health has raised $33.0M across 3 funding rounds. Most recently, it raised $10.0M Seed in July 2023.
SiPhox Health was founded in 2020 by Diedrik Vermeulen (Founder) and Michael Dubrovsky (Co-Founder).
SiPhox Health has raised $33.0M in total across 3 funding rounds.
SiPhox Health's investors include Alumni Ventures, Cyberstarts VC, FirstHand Alliance, Haun Ventures, Intel Capital, New Form Capital, Pantera Capital, The Hit Forge, Tioga Capital Partners, Y Combinator, Balaji Srinivasan, Bob Lee.
SiPhox Health is a healthcare technology company developing wearable and at-home protein and hormone monitoring devices using advanced silicon photonic chips. Their flagship product, the SiPhox Home, is a compact, lab-quality diagnostic device that enables users to perform comprehensive blood biomarker tests from a finger prick sample, delivering results in under five minutes at a fraction of traditional lab costs. This innovation targets consumers and patients seeking scalable, affordable, and convenient health monitoring solutions, addressing chronic disease management, personalized medicine, and wellness tracking with high accuracy and privacy[1][3][4][5].
Founded by experts in silicon photonics and biomedical engineering, SiPhox leverages semiconductor manufacturing techniques to miniaturize complex optical lab instruments onto silicon chips, enabling a 100x reduction in size and cost compared to conventional lab equipment. Their technology measures up to 20 proteins and hormones per test, covering cardiovascular, metabolic, inflammatory, hormonal, and immune health panels. The company is progressing toward FDA clearance and aims to expand its test menu and wearable integrations, positioning itself at the forefront of the consumer health tech and personalized diagnostics market[2][3][6][7].
---
SiPhox Health was co-founded by Diedrik Vermeulen, a pioneer in silicon photonics who contributed to the development of the first coherent silicon photonic transceiver chip used globally in internet infrastructure, and Michael Dubrovsky, CPO and co-founder with a background in biomedical technology. The idea emerged from adapting silicon photonics—originally developed for telecom and data centers—to healthcare diagnostics, enabling miniaturized, affordable, and scalable blood testing outside traditional labs. Early traction included launching a preview version using off-the-shelf components to validate consumer demand and clinical utility, supported by collaborations with AIM Photonics and validation against central lab methods[2][5][6][8].
---
---
SiPhox rides the convergence of silicon photonics technology and the growing demand for personalized, at-home health diagnostics. The timing is critical as consumers increasingly seek convenient, real-time health data outside clinical settings, driven by trends in wearable health tech, chronic disease management, and preventive care. Silicon photonics, a technology that revolutionized internet data transmission, is now being repurposed to transform medical diagnostics by enabling scalable, precise, and affordable testing. This shift supports broader healthcare trends toward decentralization, patient empowerment, and data-driven medicine, potentially reshaping how health monitoring and disease management are conducted globally[1][2][8].
---
SiPhox Health is poised to expand its impact by securing FDA clearance for its thyroid panel and launching additional tests for sex hormones, cardiac markers, inflammation, and more, all compatible with its existing device. Future trends shaping its journey include increased consumer demand for integrated health monitoring, advances in silicon photonics manufacturing, and growing acceptance of at-home diagnostics in clinical workflows. As SiPhox scales, it may influence the broader ecosystem by setting new standards for accuracy, affordability, and convenience in biomarker testing, potentially catalyzing a shift from episodic lab visits to continuous, personalized health management at home.
This trajectory ties back to SiPhox’s mission to democratize access to lab-quality diagnostics by leveraging semiconductor innovations, making health data more accessible and actionable for individuals worldwide[3][5][7].
